亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業(yè)會員第1年

隨州天豐化工科技有限公司  

化工產品﹑精細化工﹑醫(yī)藥中間體﹑機械設備

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:陳格
  • 電話:027-88393861
  • 郵件:zczzcl@163.com
  • 傳真:027-88393861
  • QQ:774811011
站內搜索
 
榮譽資質
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 阿伐他汀 CAS號: 134523-00-5
阿伐他汀 CAS號: 134523-00-5
單價 面議對比
詢價 暫無
發(fā)貨 湖北隨州市付款后3天內
過期 長期有效
更新 2022-04-28 09:39
 
詳細信息
CAS號: 134523-00-5
阿伐他汀
CAS號: 134523-00-5
中文同義詞: (3R,5R)-7-[2-(4-氟苯基)-3-苯基-4-(苯基氨基甲酰基)-5-異丙基-吡咯-1-基]-3,5-二羥基庚酸;阿托伐他汀;阿伐他汀;[R-(R^<*>^,R^<*>^)]-2-(4-氟苯基)- Β,Δ-二羥基-5-(1-甲基乙基)-3-苯基-4-[(苯基氨基)羰基]-1H-吡咯-1-庚酸;阿托他汀;阿托伐他汀(鈣鹽)
英文名稱: Atorvastatin
英文同義詞: ATORVASTATIN;ATORVASTATIN CA;ATORVASTATIN CALCIUM SALT;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid;Atorvastatin (Subject to Patent free);Atorvastatin&Ats-5Ats-8Ats-9M4L1;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid;(bR,dR)-2-(p-Fluorophenyl)-β,δ-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
分子式: C66H68CaF2N4O10
分子量: 1155.34
熔點  176-178°C
標準:USP
含量:98%
性    狀:色或類白色結晶性粉末;無臭,味苦
用途  降血脂藥。能抑制HMG-CoA還原酶的活性,從而使膽固醇合成減少。
包裝:10kg/桶
©2025 隨州天豐化工科技有限公司 版權所有   技術支持:化工網   訪問量:63059  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |